Resources
21 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/25/2021 (updated 4/5/2024)
Stimulants 2021: An Update—Clinical Issues and Treatments
The presenter will review considerations in engaging and treating individuals with stimulant use disorders and present evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 3/10/2021 (updated 4/5/2024)
This webinar provided the foundational information necessary to plan and implement effective anti-stigma strategies. We defined stigma and internalized stigma and their impact on vulnerable populations—drug policy, public perception, healthcare access. We then explored relevant resources, helpful tools, and connect with national organizations doing work in this space.
Posted 2/24/2021 (updated 4/4/2024)
This webinar provided new information on the risks and clinical challenges presented by individuals who use psychostimulants (cocaine, methamphetamine and prescription stimulants). A review of the clinical strategies that are important in working with this population were presented, including psychosocial and medication treatments for those with stimulant use disorder. Presented by Richard Rawson, Ph.D.
Posted 12/15/2020 (updated 4/3/2024)
The presenter reviewed considerations in engaging and treating individuals with stimulant use disorders and presented evidence-based treatment strategies relevant to rural communities addressing this growing problem.
Posted 11/11/2021 (updated 4/3/2024)
Joined this panel of former RCORP-Planning grantees as they shared their lessons learned and how they hit the ground running as they completed Planning and embarked on Implementation. Heard from panelists who received Implementation funding as well as those who were able to move forward without dedicated Implementation funding.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Participants learned evidenced-based harm reduction strategies to keep people who use opioids and psychostimulants alive with reduced disease burden. Presenters discussed methods of engaging people who actively use opioids and/or psychostimulants, harm reduction interventions, overdose prevention and response, overamping prevention and response, and linkages to care.
Robert Childs, MPH, JBS International
Christine Rodriguez, MPH, Vital Strategies
Posted 12/15/2020 (updated 4/3/2024)
Participants learned evidenced based harm reduction strategies to keep people who use drugs (PWUD) alive with reduced disease burden. Presenters discussed methods of engaging PWUD, linkages to MOUD, behavioral health and recovery supports for individuals ready for these supports
Posted 8/4/2021 (updated 4/2/2024)
Posted 2/25/2020 (updated 3/28/2024)
A guide to provide the addiction treatment and recovering community with practical information and tools to enhance their capacity to engage in effective stigma reduction efforts.